Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
doi: 10.1371/journal.pone.0094151
Industry attention remains focused on pipeline acquisitions and licensing as large pharmaceutical companies seek exposure to obesity and metabolic health assets
Patients with T2D are considered for CVD secondary prevention because their risk level is similar to that reported in nondiabetic patients who have already suffered a MI [3]
Some people take the drugs and lose weight with no side effects
High spikes in blood sugar = more insulin
Collectively, these factors contribute to the currently higher costs of goods compared to injectable GLP-1s, reflecting additional material, process and quality complexity along the upstream value chain
US$ 24.42
US$ 28.41
US$ 26.52
US$ 23.27
